Monday, December 15, 1997
In developing its anti-hepatitis B and anti-cytomegalovirus antibodies,
Protein Design Labs Inc. has encountered efficacy and side effect issues that reveal the
design challenges inherent in antibody development.
PDLI's Protovir anti-CMV antibody has shown limited efficacy in trials
- a common problem usually related to the appropriateness of the antibody's target to the
chosen disease indication. Meanwhile, the company's OST 577 anti-HBV antibody has
exhibited side effects unusual to MAbs, specifically formation of immune complexes
resulting in proteinuria and fever. PDLI believes the side effects are related to the
nature of the viral disease.